Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 8, Issue 1, Pages 95-102Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2015.992878
Keywords
adverse drug reactions; data mining; electronic health records; EU-ADR; FAERS; pharmacovigilance; real-world healthcare data; signal detection; spontaneous reporting systems
Categories
Ask authors/readers for more resources
A prospective pharmacovigilance signal detection study, comparing the real-world healthcare data (EU-ADR) and two spontaneous reporting system (SRS) databases, US FDA's Adverse Event Reporting System and WHO's Vigibase is reported. The study compared drug safety signals found in the EU-ADR and SRS databases. The potential for signal detection in the EU-ADR system was found to be dependent on frequency of the event and utilization of drugs in the general population. The EU-ADR system may have a greater potential for detecting signals for events occurring at higher frequency in general population and those that are commonly not considered as potentially a drug-induced event. Factors influencing various differences between the datasets are discussed along with potential limitations and applications to pharmacovigilance practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available